Noxopharm Limited (ASX:NOX) Raises $2.5 Million from Nyrada Share Sale
Funding Details
Noxopharm Limited has raised nearly $2.5 million by selling its entire shareholding in Nyrada Inc (ASX:NYR). This non-dilutive funding will support the upcoming HERACLES clinical trial and enhance the company’s R&D pipeline.
Executive Comments
CEO Dr Gisela Mautner stated, “Over the past 18 months we have gained significant momentum, and the sale of these shares will support our operations as we continue to invest in our innovative technology. We would like to thank Canary Capital for their assistance in completing this transaction and are grateful for their support throughout this process.”
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
